Freenome, Inc. (FRNM)

Freenome, Inc. is a biotechnology company developing blood tests for the early detection of cancer. Its platform combines analysis of multiple types of biological signals in a blood sample, such as cell-free DNA patterns and proteins, with machine learning to identify signatures associated with cancer.

The company's lead program is a blood-based screening test for colorectal cancer intended for average-risk adults, which has been evaluated in large prospective clinical studies, and it is working on tests for other cancer types. Freenome has partnered with diagnostics and pharmaceutical companies on development and commercialization.

Freenome is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq.